EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Can calcitonin gene‐related peptide monoclonal antibodies ameliorate writer's cramp and migraine?

Keisuke Suzuki iD, Shiho Suzuki, Hiroaki Fujita, Hirotaka Sakuramoto, Mukuto Shioda, Koichi Hirata

Neuropsychopharmacology Reports · 2024

DOI: 10.1002/npr2.12444 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Neuropsychopharmacology Reports, 2024. Verfasst von Keisuke Suzuki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Dokkyo Medical University, Mibu, Japan. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Humanized, Dystonic Disorders, Calcitonin Gene-Related Peptide. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, calcitonin gene‐related peptide (CGRP) monoclonal antibodies (mAbs) have become available as a prophylactic treatment for migraine and have shown high efficacy and safety in clinical practice. CGRP mAbs have been reported to be effective not only for migraine but also for other comorbidities, such as psychiatric complications in patients with migraine. However, there are no reports examining the effect of CGRP mAbs on dystonia. We treated a patient with comorbid migraine and focal task‐specific dystonia (writer's cramp) with a CGRP mAb (erenumab) because of an increase in monthly migraine days despite the addition of migraine prophylaxis. In this patient, erenumab treatment for 3 months led to improvements in symptoms of both focal dystonia and migraine, suggesting a role for CGRP in the pathophysiology of both conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersAntibodies, Monoclonal, HumanizedDystonic DisordersCalcitonin Gene-Related PeptideHumansAntibodies, MonoclonalFemaleMiddle AgedCalcitonin Gene-Related Peptide Receptor AntagonistsAdultMale

Stichwörter der Autor:innen

calcitonin gene‐related peptidefocal task‐specific dystoniamigraine

Substanzen

erenumabAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptideAntibodies, MonoclonalCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • Department of Neurology, Dokkyo Medical University, Mibu, Japan.

ORCID-Profile: Keisuke Suzuki

Zitieren

APA

Suzuki, K., Suzuki, S., Fujita, H., Sakuramoto, H., Shioda, M., & Hirata, K. (2024). Can calcitonin gene‐related peptide monoclonal antibodies ameliorate writer's cramp and migraine?. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12444

Vancouver

Suzuki K, Suzuki S, Fujita H, Sakuramoto H, Shioda M, Hirata K. Can calcitonin gene‐related peptide monoclonal antibodies ameliorate writer's cramp and migraine?. Neuropsychopharmacology Reports. 2024. doi:10.1002/npr2.12444

BibTeX
@article{Suzuki2024,
  author = {Suzuki, Keisuke and Suzuki, Shiho and Fujita, Hiroaki and Sakuramoto, Hirotaka and Shioda, Mukuto and Hirata, Koichi},
  title = {Can calcitonin gene‐related peptide monoclonal antibodies ameliorate writer's cramp and migraine?},
  journal = {Neuropsychopharmacology Reports},
  year = {2024},
  doi = {10.1002/npr2.12444}
}
Kostenlos starten →